Quarterly report pursuant to Section 13 or 15(d)

Operating Segments (Tables)

v3.20.2
Operating Segments (Tables)
6 Months Ended
Jun. 30, 2020
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information

The table below presents certain financial information of our operating segments for the three and six months ended June 30, 2020 and 2019 (in thousands):

 

Segment Reporting for the Quarter Ended June 30, 2020

 

    Treatment     Services     Medical     Segments
Total
    Corporate (1)     Consolidated
Total
 
Revenue from external customers   $ 7,840     $ 14,207           $ 22,047     $     $ 22,047  
Intercompany revenues     446       5             451              
Gross profit     1,695       1,615             3,310             3,310  
Research and development     52       46       74       172       37       209  
Interest income     1                   1       27       28  
Interest expense     (28 )     (4 )           (32 )     (67 )     (99 )
Interest expense-financing fees                             (60 )     (60 )
Depreciation and amortization     275       84             359       5       364  
Segment income (loss) before income taxes     750       1,031       (74 )     1,707       (1,456 )     251  
Income tax benefit     (9 )                 (9 )           (9 )
Segment income (loss)     759       1,031       (74 )     1,716       (1,456 )     260  
Expenditures for segment assets     320       146             466       2       468 (3)

 

Segment Reporting for the Quarter Ended June 30, 2019

 

    Treatment     Services     Medical     Segments
Total
    Corporate (1)    

Consolidated

Total

 
Revenue from external customers   $ 10,094     $ 7,041           $ 17,135     $     $ 17,135  
Intercompany revenues     7       42             49              
Gross profit     2,627       644             3,271             3,271  
Research and development     136             80       216       7       223  
Interest income                             107       107  
Interest expense     (30 )     (4 )           (34 )     (73 )     (107 )
Interest expense-financing fees                             (60 )     (60 )
Depreciation and amortization     233       79             312       5       317  
Segment income (loss) before income taxes     1,611       137       (80 )     1,668       (1,289 )     379  
Income tax expense     6                   6             6  
Segment income (loss)     1,605       137       (80 )     1,662       (1,289 )     373  
Expenditures for segment assets     73       15             88             88 (2)

 

Segment Reporting for the Six Months Ended June 30, 2020

 

    Treatment     Services     Medical     Segments
Total
    Corporate (1)     Consolidated
Total
 
Revenue from external customers   $ 17,403     $ 29,504           $ 46,907     $     $ 46,907  
Intercompany revenues     653       13             666              
Gross profit     4,440       3,510             7,950             7,950  
Research and development     145       112       140       397       44       441  
Interest income     1                   1       83       84  
Interest expense     (46 )     (10 )           (56 )     (163 )     (219 )
Interest expense-financing fees                             (129 )     (129 )
Depreciation and amortization     539       162             701       10       711  
Segment income (loss) before income taxes     2,297       2,349       (140 )     4,506       (2,933 )     1,573  
Income tax expense     5                   5             5  
Segment income (loss)     2,292       2,349       (140 )     4,501       (2,933 )     1,568  
Expenditures for segment assets     1,000       361             1,361       5       1,366 (3)

 

Segment Reporting for the Six Months Ended June 30, 2019

 

    Treatment     Services     Medical     Segments
Total
    Corporate (1)     Consolidated
Total
 
Revenue from external customers   $ 19,999     $ 8,844           $ 28,843     $     $ 28,843  
Intercompany revenues     9       63             72              
Gross profit     5,584       188             5,772             5,772  
Research and development     283             154       437       13       450  
Interest income                             188       188  
Interest expense     (47 )     (13 )           (60 )     (134 )     (194 )
Interest expense-financing fees                             (70 )     (70 )
Depreciation and amortization     470       157             627       14       641  
Segment income (loss) before income taxes     3,487       (875 )     (154 )     2,458       (2,590 )     (132 )
Income tax expense     45                   45             45  
Segment income (loss)     3,442       (875 )     (154 )     2,413       (2,590 )     (177 )
Expenditures for segment assets     294       18             312             312 (2)

 

(1) Amounts reflect the activity for corporate headquarters not included in the segment information.

 

(2) Net of financed amount of $18,000 and $22,000 for the three and six months ended June 30, 2019, respectively.

 

(3) Net of financed amount of $51,000 and $132,000 for the three and six months ended June 30, 2020, respectively.